Disease-free and overall survival rates at 6 years were 61% and 74%, respectively, among patients with mutation clearance at ...

Driver mutations are the pathophysiological hallmark ... More than half the patients had been exposed to JAK inhibitor therapy before transplantation.

Only MPL W515 mutations induced (1) Ba/F3 proliferation independently of growth factors, (2) tumorigenesis in nude mice, (3) spontaneous activation of JAK/STAT, RAS/MAPK and PI3K transduction ...

Another 45 years passed before the discovery of a first genetic driver of non-Ph MPNs, a mutation in the Janus kinase 2 (JAK2 ...

A panelist discusses how patients with polycythemia vera (PV) often present with diverse symptoms ranging from fatigue and itching to cardiovascular complications, leading doctors to conduct specific ...

A panelist discusses how polycythemia vera (PV) is a rare myeloproliferative neoplasm (MPN) characterized by excessive red blood cell production, primarily affecting older adults with JAK2 mutations, ...

New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has ...